The HCP's hesitation to initiate a cessation conversation has historically been, in part, rooted in a perceived lack of practical tools to offer patients who express readiness to quit but face barriers to clinic-based pharmacotherapy. Safer Novel Alternatives — including nicotine e-cigarettes and other SNA formulations — are now shifting that calculus by providing cessation-motivated smokers with options that fit their daily realities.